Show simple item record

dc.contributor.authorMatias-Guiu, Xavier
dc.contributor.authorStanta, Giorgio
dc.contributor.authorCarneiro, Fátima
dc.contributor.authorRyska, Ales
dc.contributor.authorHoefler, Gerald
dc.contributor.authorMoch, Holger
dc.description.abstractMolecular pathology is an essential part of pathology complementing conventional morphological tools to obtain a correct integrated diagnosis with appropriate assessment of prognosis and prediction of response to therapy, particularly in cancer. There is a concern about the situation of molecular pathology in some areas of Europe, namely, regarding the central role of pathologists in assessing somatic genomic alterations in cancer. In some countries, there are attempts that other laboratory medicine specialists perform the molecular analysis of somatic alterations in cancer, particularly now when next generation sequencing (NGS) is incorporated into clinical practice. In this scenario, pathologists may play just the role of "tissue providers," and other specialists may take the lead in molecular analysis. Geneticists and laboratory medicine specialists have all background and skills to perform genetic analysis of germline alterations in hereditary disorders, including familial forms of cancers. However, interpretation of somatic alterations of cancer belongs to the specific scientific domain of pathology. Pathologists are necessary to guarantee the quality of the results, for several reasons: (1) The identified molecular alterations should be interpreted in the appropriate morphologic context, since most of them are context-specific; (2) pre-analytical issues must be taken into consideration; (3) it is crucial to check the proportion of tumor cells in the sample subjected to analysis and presence of inflammatory infiltrate and necrosis should be monitored; and 4) the role of pathologists is crucial to select the most appropriate methods and to control the turnaround time in which the molecular results are delivered in the context of an integrated diagnosis. Obviously, there is the possibility of having core facilities for NGS in a hospital to perform the sequence analysis that are open to other specialties (microbiologists, geneticists), but also in this scenario, pathologists should have the lead in assessing somatic alterations of cancer. In this article, we emphasize the importance of interpreting somatic molecular alterations of the tumors in the context of morphology. In this Position Paper of the European Society of Pathology, we strongly support a central role of pathology departments in the process of analysis and interpretation of somatic molecular alterations in cancer.ca_ES
dc.description.sponsorshipThe proposal for this position paper was approved by the Publication Task Force of the European Society of Pathology (ESP), and this approval was subsequently verified by the Council of ESP. We thank Mar Varela, Dolors Cuevas, Ana Velasco and Jordi Temprana for help in writing the manuscript.ca_ES
dc.publisherSpringer Natureca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofVirchows Archiv, 2020, vol. 476, p. 491-497ca_ES
dc.rightscc-by, (c) Matias-Guiu et al., 2020ca_ES
dc.subjectMolecular pathologyca_ES
dc.subjectPre-analytical issuesca_ES
dc.subjectIntegrative pathologyca_ES
dc.titleThe leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathologyca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by, (c) Matias-Guiu et al., 2020
Except where otherwise noted, this item's license is described as cc-by, (c) Matias-Guiu et al., 2020